/what-is-beyfortus.jpg.aspx)
The child's age on the day the infant RSV antibody is administered should be used to determine if the child is eligible for immunization. Except in rare circumstances, an infant RSV antibody is not needed for most infants who are born 14 or more days after their mother received RSV vaccine. Beyfortus is indicated for the prevention of RSV lower respiratory tract disease in 1: Neonates and infants born during or entering their first RSV season.
Children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season. Beyfortus is a prescription medicine used to help prevent a serious lung disease caused by Respiratory Syncytial Virus (RSV) in: Newborns and babies under 1 year of age born during or entering their first RSV season. A total of 3,224 pediatric subjects received the recommended dose of BEYFORTUS in Phase 2 and Phase 3 clinical trials (Trials 03, 04, and 05) including 2,119 infants who were born at 35 weeks gestational age (GA) or older, and 1,105 infants who were born at less than 35 weeks GA.
Beyfortus is used to prevent respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants born during or entering their first RSV season. It may also be given to children up to 24 months of age who remain at risk of severe RSV disease through their second RSV season. Beyfortus helps to protect healthy and at.
Rx Only PATIENT INFORMATION BEYFORTUS® (Bay for tus) (nirsevimab-alip) injection, for intramuscular use What is BEYFORTUS? t is used to help prevent a serious lung disease caused by Respiratory Syncytial Virus (RSV newborns and babies under 1 year of age born during or entering their first RSV season. RSV Preventive Antibodies The RSV preventive antibody (generic name nirsevimab, trade name Beyfortus) is a shot that prevents severe RSV disease in infants and young children. Antibodies are proteins that the body's immune system uses to fight off harmful germs.
Beyfortus is the first and only long-acting antibody indicated for the prevention of RSV lower respiratory tract disease in3: Neonates and infants born during or entering their first RSV season Children up to 24 months of age who remain vulnerable to severe RSV disease through their American Academy Pediatrics; ACIP. Trial 05, a randomized, double-blind, active (palivizumab)-controlled, multicenter trial, supported the use of Beyfortus in in children up to 24 months of age who remain vulnerable to severe RSV. About Beyfortus In the U.S., Beyfortus is a single.
